Reply to Lipworth and Chan

Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE.

¹ Respiratory and Immunology, BioPharmaceuticals Medical.
² Pulmonary and Critical Care Medicine, Allergy & Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Biometrics, Late-stage Development.
⁴ Global Medical Affairs.
⁵ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
⁶ University of Leicester, Leicester, United Kingdom.
⁷ Biometrics, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
⁸ IKF Pneumologie Mainz, Mainz, Germany.
⁹ Thoraxklinik Heidelberg, Heidelberg, Germany; and.
¹⁰ Royal Brompton and Harefield Hospitals, London, United Kingdom.
¹¹ Global Development, and.
¹² Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
¹³ Translational Medicine, Amgen, Thousand Oaks, California.

No abstract available

Grants and funding